Display options
Cite
Lawson DH, Bridgman K, de Bock GH, et al. European postmarketing surveillance of ramipril in hypertension. 1. Feasibility and study cohort. Eur J Clin Pharmacol. 1995;49(1):73-9doi: 10.1007/BF00192362.
Lawson, D. H., Bridgman, K., de Bock, G. H., Grobbee, D. E., Hense, H. W., Block, P., Paterson, K. R., & Stonier, P. (1995). European postmarketing surveillance of ramipril in hypertension. 1. Feasibility and study cohort. European journal of clinical pharmacology, 49(1), 73-9. https://doi.org/10.1007/BF00192362
Lawson, D H, et al. "European postmarketing surveillance of ramipril in hypertension. 1. Feasibility and study cohort." European journal of clinical pharmacology vol. 49,1 (1995): 73-9. doi: https://doi.org/10.1007/BF00192362
Lawson DH, Bridgman K, de Bock GH, Grobbee DE, Hense HW, Block P, Paterson KR, Stonier P. European postmarketing surveillance of ramipril in hypertension. 1. Feasibility and study cohort. Eur J Clin Pharmacol. 1995;49(1):73-9. doi: 10.1007/BF00192362. PMID: 8751025.
Copy Download .nbib Format: NLM
Share it on
Full text links
Springer

Eur J Clin Pharmacol. 1995;49(1):73-9. doi: 10.1007/BF00192362.

European postmarketing surveillance of ramipril in hypertension. 1. Feasibility and study cohort.

European journal of clinical pharmacology

D H Lawson, K Bridgman, G H de Bock, D E Grobbee, H W Hense, P Block, K R Paterson, P Stonier

Affiliations

  1. Ramipril Postmarketing Surveillance Study, Glasgow.

PMID: 8751025 DOI: 10.1007/BF00192362

Abstract

A prospective observational cohort study of the angiotensin inhibitor, ramipril, was undertaken in four countries within the European Community-Netherlands, United Kingdom, Germany and Belgium. A total of 10,377 consecutive patients with essential hypertension were recruited to the study with the aim of follow-up for one year. Overall 37% of doctors who agreed to participate in the study actually enrolled at least one patient. One third of the doctors who enrolled patients in the study entered two thirds of patients studied. Some 15% of participating males and 27% of females were aged over 70 years. Newly diagnosed hypertensives comprised 22% of the study cohort, the proportion being highest in UK and Netherlands, whereas 53% were established hypertensives of two or more years' duration, the proportion being highest in Germany and Belgium. There were substantial differences among the participating countries in the concurrent treatment these patients were receiving for hypertension, with two or more co-therapies being most frequent in Germany and Belgium. There were also substantial differences in co-therapies for concurrent diseases among the participating countries, reflecting both standard therapeutic practices in local areas and differences in marketing of drugs in the different countries. This report describes the initial findings of this multinational study and emphasises the need to consider several major potentially confounding variables in the analysis of the outcome events both in this study and in other collaborative observational international monitoring schemes for adverse drug reactions.

References

  1. Lancet. 1993 Nov 6;342(8880):1179 - PubMed
  2. Br Med J (Clin Res Ed). 1982 Nov 6;285(6351):1311-3 - PubMed
  3. Ann Ist Super Sanita. 1991;27(2):201-6 - PubMed
  4. BMJ. 1992 Jun 6;304(6840):1470-2 - PubMed
  5. Br Med J. 1977 Jan 8;1(6053):96-7 - PubMed
  6. J Clin Epidemiol. 1992 Dec;45(12):1423-30 - PubMed
  7. J R Coll Gen Pract. 1987 Aug;37(301):346-9 - PubMed
  8. Artery. 1992;19(3):147-61 - PubMed
  9. Drugs. 1990;40 Suppl 5:43-7 - PubMed
  10. Br Med J (Clin Res Ed). 1981 Apr 4;282(6270):1131-2 - PubMed
  11. Lancet. 1993 Nov 6;342(8880):1178 - PubMed
  12. Br Med J (Clin Res Ed). 1984 Mar 24;288(6421):911-4 - PubMed
  13. Br Med J. 1979 Jul 21;2(6183):163-5 - PubMed
  14. Eur J Clin Pharmacol. 1990;39(1):1-7 - PubMed
  15. BMJ. 1988 Oct 1;297(6652):826-9 - PubMed
  16. Br Med J. 1977 Mar 12;1(6062):691-2 - PubMed
  17. Br J Clin Pharmacol. 1992 Sep;34(3):215-23 - PubMed
  18. Drugs. 1990;40 Suppl 5:80-6 - PubMed
  19. Br J Clin Pharmacol. 1987 Sep;24(3):343-9 - PubMed
  20. Int J Clin Pharmacol Ther Toxicol. 1990 Jul;28(7):312-4 - PubMed
  21. Lancet. 1993 Sep 11;342(8872):658-61 - PubMed
  22. Eur J Clin Pharmacol. 1992;42(5):555-7 - PubMed
  23. Klin Wochenschr. 1991 Oct 31;69(17):775-9 - PubMed
  24. BMJ. 1988 Oct 1;297(6652):830-2 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources